Mr. Victor Tong, Jr. is a Managing Director at Decheng Capital and has been with the firm since its inception.

Mr. Tong focuses on investments in biotechnology and medical technology companies in the US and China. He currently serves on the boards of Aardvark Therapeutics, Cellares, CG Oncology (NASDAQ: CGON), Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Nalu Medical, Take2 and Watchmaker Genomics. Previously, Mr. Tong served as Chairman at ReadCoor before its acquisition by 10X Genomics. He also held board positions at Cirina (acquired by GRAIL / Illumina) and GeneWEAVE Biosciences (acquired by Roche).

Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley.

Mr. Tong holds a B.A. in Molecular and Cell Biology and B.S. in Business Administration from the University of California, Berkeley.